ScinoPharm’s Tainan, Taiwan Facility will provide commercial manufacture of topiramate API for VIVUS’ Qsymia, a recently approved drug for the treatment of obesity. Qsymia is the first FDA-approved once daily combination treatment for chronic weight management in adults who are obese or overweight with a weight-related comorbidity. It is a combination of an anticonvulsant, topiramate, and appetite suppressant, phentermine.   “ScinoPharm is proud of our longstanding partnership with V...